Plasticity of type I interferon-mediated responses in cancer therapy: From anti-tumor immunity to resistance

Frontiers in Oncology

Volumn 8, Issue AUG, 2018, Pages

  Budhwani, Megha ^a   Mazzieri, Roberta ^a   Dolcetti, Riccardo ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cancer immunotherapy; Immune responses; Interferons; Resistance mechanisms; Tumor microenvironment

Indexed keywords

IMMUNOLOGICAL ANTINEOPLASTIC AGENT; INTERFERON; INTERFERON RECEPTOR; JANUS KINASE; MICRORNA; ONCOLYTIC VIRUS; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY; DOWN REGULATION; HUMAN; JAK-STAT SIGNALING; LONG TERM EXPOSURE; NONHUMAN; ONCOLYTIC VIROTHERAPY; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; UPREGULATION;

EID: 85051851989     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2018.00322     Document Type: Review

References (149)

1. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. (2017) 15:81-94. doi: 10.1038/nrclinonc.2017.166
2. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell (2012) 21:283-96. doi: 10.1016/j.ccr.2012.03.003
3. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. (2006) 6:836. doi: 10.1038/nri1961
4. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, de Sanmamed MF, Le Bon A, Melero IJ. Direct Effects of type I IFNs on cells of the immune system. Clin Cancer Res. (2011) 17:2619-27. doi: 10.1158/1078-0432.CCR-10-1114
5. Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer (2016) 16:131. doi: 10.1038/nrc.2016.14
6. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nature Reviews Immunol. (2015) 15:405. doi: 10.1038/nri3845
7. Indraccolo S. Interferon-a as angiogenesis inhibitor: learning from tumor models. Autoimmunity (2010) 43:244-7. doi: 10.3109/08916930903510963
8. Snell LM, McGaha TL, Brooks DG. Type I interferon in chronic virus infection and cancer. Trends Immunol. (2017) 38:542-57. doi: 10.1016/j.it.2017.05.005
9. Medrano RF, Hunger A, Mendonça SA, Barbuto JAM, Strauss BE. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget (2017) 8:71249. doi: 10.18632/oncotarget.19531
10. Chen K, Liu J, Cao X. Regulation of type I interferon signaling in immunity and inflammation: a comprehensive review. J Autoimmun. (2017) 83:1-11. doi: 10.1016/j.jaut.2017.03.008
11. Arimoto KI, Miyauchi S, Stoner SA, Fan JB, Zhang DE. Negative regulation of type I IFN signaling. J Leukoc Biol. (2018). 103:1099-116. doi: 10.1002/JLB.2MIR0817-342R
12. Hertzog PJ, Williams BR. Fine tuning type I interferon responses. Cytokine Growth Factor Rev. (2013) 24:217-25. doi: 10.1016/j.cytogfr.2013.04.002
13. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. (2014) 14:36. doi: 10.1038/nri3581
14. Bhat N, Fitzgerald KA. Recognition of cytosolic DNA by cGAS and other STING-dependent sensors. Eur. J. Immunol. (2014) 44:634-40. doi: 10.1002/eji.201344127
15. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity (2014) 41:843-52. doi: 10.1016/j.immuni.2014.10.019
16. Iwanaszko M, Kimmel M. NF-κB and IRF pathways: cross-regulation on target genes promoter level. BMC Genomics (2015) 16:307. doi: 10.1186/s12864-015-1511-7
17. Solis M, Goubau D, Romieu-Mourez R, Genin P, Civas A, Hiscott J. Distinct functions of IRF-3 and IRF-7 in IFN-alpha gene regulation and control of anti-tumor activity in primary macrophages. Biochem Pharmacol. (2006) 72:1469-76. doi: 10.1016/j.bcp.2006.06.002
18. Schindler C, Fu X-Y, Improta T, Aebersold R, Darnell JE. Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha. Proc Natl Acad Sci USA. (1992) 89:7836-9. doi: 10.1073/pnas.89.16.7836
19. Cheon H, Stark GR. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci USA. (2009) 106:9373-8. doi: 10.1073/pnas.0903487106
20. Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol. (2011) 1:519-25. doi: 10.1016/j.coviro.2011.10.008
21. Cheon H, Borden EC, Stark GR. Interferons and their stimulated genes in the tumor microenvironment. Semin Oncol. (2014) 41:156-73. doi: 10.1053/j.seminoncol.2014.02.002
22. Mastorci K, Montico B, Faè DA, Sigalotti L, Ponzoni M, Inghirami G, et al. Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma. Oncotarget (2016) 7:41913. doi: 10.18632/oncotarget.9630
23. Wilmes S, Beutel O, Li Z, Francois-Newton V, Richter CP, Janning D, et al. Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling. J Cell Biol. (2015) 209:579-93. doi: 10.1083/jcb.201412049
24. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang D-E. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem. (2002) 277:9976-81. doi: 10.1074/jbc.M109078200
25. Shi HX, Yang K, Liu X, Liu XY, Wei B, Shan YF, et al. Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol Cell Biol. (2010) 30:2424-36. doi: 10.1128/MCB.01466-09
26. Slone HB, Peters LJ, Milas L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma 2. J Natl Cancer Inst. (1979) 63:1229-35. Google Scholar
27. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. (2011) 71:2488-96. doi: 10.1158/0008-5472.CAN-10-2820
28. Lim JY, Gerber SA, Murphy SP, Lord EM. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells. Cancer Immunol Immunother. (2014) 63:259-71. doi: 10.1007/s00262-013-1506-7
29. Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. (2015) 41:503-10. doi: 10.1016/j.ctrv.2015.03.011
30. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. (2005) 202:1691-701. doi: 10.1084/jem.20050915
31. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. (2007) 13:1050-9. doi: 10.1038/nm1622
32. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. (2011) 8:151-60. doi: 10.1038/nrclinonc.2010.223
33. Vacchelli E, Sistigu A, Yamazaki T, Vitale I, Zitvogel L, Kroemer G. Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. Oncoimmunology (2015) 4:e988042. doi: 10.4161/2162402X.2014.988042
34. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. (2014) 20:1301-9. doi: 10.1038/nm.3708
35. Leukemia ICSGoCM. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. (1994) 1994:820-5. Google Scholar
36. Latagliata R, Romano A, Mancini M, Breccia M, Carmosino I, Vozella F, et al. Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response. Leuk Lymphoma. (2016) 57:99-102. doi: 10.3109/10428194.2015.1043548
37. Simonsson B, Gedde-Dahl T, Markevärn B, Remes K, Stentoft J, Almqvist A, et al. Combination of pegylated IFN-a2b with imatinib increases molecular response rates in patients with low-or intermediate-risk chronic myeloid leukemia. Blood (2011) 118:3228-35. doi: 10.1182/blood-2011-02-336685
38. Rousselot P, Preudhomme C, Guilhot J, Dubruille V, Lamy T, Delain M, et al. Molecular responses of the Spirit phase III trial of the French CML Group comparing imatinib 400 mg to higher dose imatinib or combination with interferon or cytarabine for the treatment of newly diagnosed chronic phase (cp) chronic myeloid leukaemia (CML) patients. Haematologica (2009) 94:441
39. Burchert A, Müller MC, Kostrewa P, Erben P, Bostel T, Liebler S, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol. (2010) 28:1429-35. doi: 10.1200/JCO.2009.25.5075
40. Rautela J, Baschuk N, Slaney CY, Jayatilleke KM, Xiao K, Bidwell BN, et al. Loss of host type-I IFN signaling accelerates metastasis and impairs NK-cell antitumor function in multiple models of breast cancer. Cancer Immunol. Res. (2015) 3:1207-17. doi: 10.1158/2326-6066.CIR-15-0065
41. Slaney CY, Möller A, Hertzog PJ, Parker BS. The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone. Oncoimmunology (2013) 2:e22339. doi: 10.4161/onci.22339
42. Legrier M-E, Bièche I, Gaston J, Beurdeley A, Yvonnet V, Déas O, et al. Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer. Br J Cancer (2016) 114:177. doi: 10.1038/bjc.2015.398
43. Recchia F, Sica G, Candeloro G, Necozione S, Bisegna R, Bratta M, et al. Beta-interferon, retinoids and tamoxifen in metastatic breast cancer: long-term follow-up of a phase II study. Oncol Rep. (2009) 21:1011-6. doi: 10.3892/or_00000317
44. Ma C, Armstrong AW. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. J Dermatol Treat. (2014) 25:401-8. doi: 10.3109/09546634.2013.813897
45. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-a. CNS Drugs (2005) 19:105-23. doi: 10.2165/00023210-200519020-00002
46. Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J Interf Cytokine Res. (1996) 16:759-64. doi: 10.1089/jir.1996.16.759
47. Kontermann RE. Half-life extended biotherapeutics. Expert Opin Biol Ther. (2016) 16:903-15. doi: 10.1517/14712598.2016.1165661
48. Fam CM, Eisenberg SP, Carlson SJ, Chlipala EA, Cox GN, Rosendahl MS. PEGylation improves the pharmacokinetic properties and ability of interferon gamma to inhibit growth of a human tumor xenograft in athymic mice. J Interfer Cytokine Res. (2014) 34:759-68. doi: 10.1089/jir.2013.0067
49. Kusano H, Akiba J, Ogasawara S, Sanada S, Yasumoto M, Nakayama M, et al. Pegylated interferon-a2a inhibits proliferation of human liver cancer cells in vitro and in vivo. PloS ONE (2013) 8:e83195. doi: 10.1371/journal.pone.0083195
50. Iwamura T, Narumi H, Suzuki T, Yanai H, Mori K, Yamashita K, et al. Novel pegylated interferon-β as strong suppressor of the malignant ascites in a peritoneal metastasis model of human cancer. Cancer Sci. (2017) 108:581-9. doi: 10.1111/cas.13176
51. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. (2008) 372:117-26. doi: 10.1016/S0140-6736(08)61033-8
52. Eigentler T, Gutzmer R, Hauschild A, Heinzerling L, Schadendorf D, Nashan D, et al. Adjuvant treatment with pegylated interferon a-2a versus low-dose interferon a-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. Ann Oncol. (2016) 27:1625-32. doi: 10.1093/annonc/mdw225
53. Escobar G, Gentner B, Naldini L, Mazzieri R. Engineered tumor-infiltrating macrophages as gene delivery vehicles for interferon-a activates immunity and inhibits breast cancer progression. Oncoimmunology (2014) 3:e28696. doi: 10.4161/onci.28696
54. Escobar G, Moi D, Ranghetti A, Ozkal-Baydin P, Squadrito ML, Kajaste-Rudnitski A, et al. Genetic engineering of hematopoiesis for targeted IFN-a delivery inhibits breast cancer progression. Sci Translat Med. (2014) 6:217ra3. doi: 10.1126/scitranslmed.3006353
55. De Palma M, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G, et al. Tumor-targeted interferon-a delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell (2008) 14:299-311. doi: 10.1016/j.ccr.2008.09.004
56. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 12:252. doi: 10.1038/nrc3239
57. Sharma P, Allison JP. The future of immune checkpoint therapy. Science (2015) 348:56-61. doi: 10.1126/science.aaa8172
58. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. (2013) 2013:134-44. doi: 10.1056/NEJMoa1305133
59. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell (2016) 167:397-404. e9. doi: 10.1016/j.cell.2016.08.069
60. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol. (2005) 6:722. doi: 10.1038/ni1213
61. Woo S-R, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity (2014) 41:830-42. doi: 10.1016/j.immuni.2014.10.017
62. Wang Z, Wu Z, Liu Y, Han W. New development in CAR-T cell therapy. J Hematol Oncol. (2017) 10:53. doi: 10.1186/s13045-017-0423-1
63. Grupp SA, Maude SL, Shaw PA, Aplenc R, Barrett DM, Callahan C, et al. Durable remissions in children with relapsed/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Am Soc Hematol. (2015) 126:681. Google Scholar
64. Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, et al. Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell. (2017) 31:194-207. doi: 10.1016/j.ccell.2017.01.004
65. Yong CS, Dardalhon V, Devaud C, Taylor N, Darcy PK, Kershaw MH. CAR T-cell therapy of solid tumors. Immunol Cell Biol. (2017) 95:356-63. doi: 10.1038/icb.2016.128
66. Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets (2017) 18:171-6. doi: 10.2174/1568009618666171129221503
67. Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer (2016) 4:53. doi: 10.1186/s40425-016-0158-5
68. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. (2006) 12:6737-47. doi: 10.1158/1078-0432.CCR-06-0759
69. Kaufman HL, Andtbacka RH, Collichio FA, Wolf M, Zhao Z, Shilkrut M, et al. Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. J Immunother Cancer (2017) 5:72. doi: 10.1186/s40425-017-0276-8
70. Hummel JL, Safroneeva E, Mossman KL. The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mole Ther. (2005) 12:1101-10. doi: 10.1016/j.ymthe.2005.07.533
71. Zhang Kx, Matsui Y, Hadaschik BA, Lee C, Jia W, Bell JC, et al. Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death. Int J Cancer (2010) 127:830-8. doi: 10.1002/ijc.25088
72. Li Q, Tainsky MA. Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses. PLoS ONE (2011) 6:e28683. doi: 10.1371/journal.pone.0028683
73. Wagner TC, Velichko S, Chesney SK, Biroc S, Harde D, Vogel D, et al. Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int J Cancer (2004) 111:32-42. doi: 10.1002/ijc.20236
74. Zheng H, Qian J, Carbone CJ, Leu NA, Baker DP, Fuchs SY. Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis. Blood (2011) 118:4003-6. doi: 10.1182/blood-2011-06-359745
75. Bhattacharya S, HuangFu W-C, Dong G, Qian J, Baker DP, Karar J, et al. Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses. Oncogene (2013) 32:4214-21. doi: 10.1038/onc.2012.439
76. HuangFu W-C, Qian J, Liu C, Liu J, Lokshin AE, Baker DP, et al. Inflammatory signaling compromises cell responses to interferon alpha. Oncogene (2012) 31:161-72. doi: 10.1038/onc.2011.221
77. Liu J, HuangFu W-C, Kumar KS, Qian J, Casey JP, Hamanaka RB, et al. Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Cell Host Microbe (2009) 5:72-83. doi: 10.1016/j.chom.2008.11.008
78. Vanacker H, Vetters J, Moudombi L, Caux C, Janssens S, Michallet M-C. Emerging role of the unfolded protein response in tumor immunosurveillance. Trends Cancer (2017) 3:491-505. doi: 10.1016/j.trecan.2017.05.005
79. Katlinskaya YV, Katlinski KV, Yu Q, Ortiz A, Beiting DP, Brice A, et al. Suppression of type I interferon signaling overcomes oncogene-induced senescence and mediates melanoma development and progression. Cell Rep. (2016) 15:171-80. doi: 10.1016/j.celrep.2016.03.006
80. Rodvold JJ, Chiu KT, Hiramatsu N, Nussbacher JK, Galimberti V, Mahadevan NR, et al. Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells. Sci Signal. (2017) 10:eaah7177. doi: 10.1126/scisignal.aah7177
81. Tomita S, Ishibashi K, Hashimoto K, Sugino T, Yanagida T, Kushida N, et al. Suppression of SOCS3 increases susceptibility of renal cell carcinoma to interferon-a. Cancer Sci. (2011) 102:57-63. doi: 10.1111/j.1349-7006.2010.01751.x
82. Zitzmann K, Brand S, De Toni EN, Baehs S, Göke B, Meinecke J, et al. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res. (2007) 67:5025-32. doi: 10.1158/0008-5472.CAN-06-2575
83. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Cervantes F, Barrios M, Colomer D, et al. The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. Haematologica (2004) 89:42-8
84. Beaurivage C, Champagne A, Tobelaim WS, Pomerleau V, Menendez A, Saucier C. SOCS1 in cancer: an oncogene and a tumor suppressor. Cytokine (2016) 82:87-94. doi: 10.1016/j.cyto.2016.01.005
85. Dunn GP, Sheehan KC, Old LJ, Schreiber RD. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. (2005) 65:3447-53. doi: 10.1158/0008-5472.CAN-04-4316
86. Romero-Weaver AL, Wang H-W, Steen HC, Scarzello AJ, Hall VL, Sheikh F, et al. Resistance to IFN-a-induced apoptosis is linked to a loss of STAT2. Mol Cancer Res. (2010) 8:80-92. doi: 10.1158/1541-7786.MCR-08-0344
87. Wu W-Z, Sun H-C, Gao Y-Q, Li Y, Wang L, Zhou K, et al. Reduction in p48-ISGF? levels confers resistance to interferon-a2a in MHCC97 cells. Oncology (2004) 67:428-40. doi: 10.1159/000082928
88. Landolfo S, Guarini A, Riera L, Gariglio M, Gribaudo G, Cignetti A, et al. Chronic myeloid leukemia cells resistant to interferon-a lack STAT1 expression. Hematol J. (2000) 1:14. doi: 10.1038/sj.thj.6200004
89. Wellbrock C, Weisser C, Hassel JC, Fischer P, Becker J, Vetter CS, et al. STAT5 contributes to interferon resistance of melanoma cells. Curr Biol. (2005) 15:1629-39. doi: 10.1016/j.cub.2005.08.036
90. Shang D, Liu Y, Ito N, Kamoto T, Ogawa O. Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-a resistance. Cancer Sci. (2007) 98:1259-64. doi: 10.1111/j.1349-7006.2007.00526.x
91. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. (2012) 18:1224-31. doi: 10.1038/nm.2830
92. Zhao Y, Chen W, Zhu W, Meng H, Chen J, Zhang J. Overexpression of interferon regulatory factor 7 (IRF7) reduces bone metastasis of prostate cancer cells in mice. Oncol Res Featur Preclin Clin Cancer Ther. (2017) 25:511-22. doi: 10.3727/096504016X14756226781802
93. Bi X, Hameed M, Mirani N, Pimenta EM, Anari J, Barnes BJ. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res. (2011) 13:R111. doi: 10.1186/bcr3053
94. Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S, et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-a/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer (2010) 103:1617-26. doi: 10.1038/sj.bjc.6605958
95. Tomokuni A, Eguchi H, Tomimaru Y, Wada H, Kawamoto K, Kobayashi S, et al. miR-146a suppresses the sensitivity to interferon-a in hepatocellular carcinoma cells. Biochem Biophys Res Commun. (2011) 414:675-80. doi: 10.1016/j.bbrc.2011.09.124
96. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer (2010) 127:1785-94. doi: 10.1002/ijc.25191
97. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. (2016) 375:819-29. doi: 10.1056/NEJMoa1604958
98. Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. (2017) 7:188-201. doi: 10.1158/2159-8290.CD-16-1223
99. Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, et al. Impaired HLA Class I Antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. (2017) 7:1420-35. doi: 10.1158/2159-8290.CD-17-0593
100. Marozin S, Altomonte J, Stadler F, Thasler WE, Schmid RM, Ebert O. Inhibition of the IFN-β response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3. Mol Ther. (2008) 16:1789-97. doi: 10.1038/mt.2008.201
101. Murphy AM, Besmer DM, Moerdyk-Schauwecker M, Moestl N, Ornelles DA, Mukherjee P, et al. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol. (2012) 86:3073-87. doi: 10.1128/JVI.05640-11
102. Moerdyk-Schauwecker M, Shah NR, Murphy AM, Hastie E, Mukherjee P, Grdzelishvili VZ. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology (2013) 436:221-34. doi: 10.1016/j.virol.2012.11.014
103. Saloura V, Wang LCS, Fridlender ZG, Sun J, Cheng G, Kapoor V, et al. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-β for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther. (2009) 21:51-64. doi: 10.1089/hum.2009.088
104. Paglino JC, van den Pol AN. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J Virol. (2011) 85:9346-58. doi: 10.1128/JVI.00723-11
105. Guo B, Hu B, Zhao L, Wu K, Wu Y, Liu H. Increased VSV oncolytic sensitivity in tumor cells by down-regulation of Mx1 gene expression. Int J Clin Exp Med. (2016) 9:3746-51. Google Scholar
106. Sobol P, Hummel J, Rodrigues R, Mossman K. PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses. Gene Ther. (2009) 16:1077-87. doi: 10.1038/gt.2009.68
107. Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell (2016) 167:1540-54. e12. doi: 10.1016/j.cell.2016.11.022
108. Gato-Ca-as M, Zuazo M, Arasanz H, Iba-ez-Vea M, Lorenzo L, Fernandez-Hinojal G, et al. PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell Rep. (2017) 20:1818-29. doi: 10.1016/j.celrep.2017.07.075
109. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 520:373-7. doi: 10.1038/nature14292
110. Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, Okazaki T, et al. IFN-a directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol. (2011) 186:2772-9. doi: 10.4049/jimmunol.1003208
111. Khodarev NN, Beckett M, Labay E, Darga T, Roizman B, Weichselbaum RR. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci USA. (2004) 101:1714-9. doi: 10.1073/pnas.0308102100
112. Khodarev NN, Minn AJ, Efimova EV, Darga TE, Labay E, Beckett M, et al. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res. (2007) 67:9214-20. doi: 10.1158/0008-5472.CAN-07-1019
113. Tsai MH, Cook JA, Chandramouli GV, DeGraff W, Yan H, Zhao S, et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res. (2007) 67:3845-52. doi: 10.1158/0008-5472.CAN-06-4250
114. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA. (2008) 105:18490-5. doi: 10.1073/pnas.0809242105
115. Duarte CW, Willey CD, Zhi D, Cui X, Harris JJ, Vaughan LK, et al. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS ONE (2012) 7:e29653. doi: 10.1371/journal.pone.0029653
116. Cheon H, Holvey-Bates EG, Schoggins JW, Forster S, Hertzog P, Imanaka N, et al. IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J. (2013) 32:2751-63. doi: 10.1038/emboj.2013.203
117. Rickardson L, Fryknäs M, Dhar S, Lövborg H, Gullbo J, Rydåker M, et al. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer (2005) 93:483-92. doi: 10.1038/sj.bjc.6602699
118. Qadir AS, Ceppi P, Brockway S, Law C, Mu L, Khodarev NN, et al. CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response. Cell Rep. (2017) 18:2373-86. doi: 10.1016/j.celrep.2017.02.037
119. Ceppi P, Hadji A, Kohlhapp FJ, Pattanayak A, Hau A, Liu X, et al. CD95 and CD95L promote and protect cancer stem cells. Nat Commun. (2014) 5:5238. doi: 10.1038/ncomms6238
120. Krause M, Dubrovska A, Linge A, Baumann M. Cancer stem cells: radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Adv Drug Deliv Rev. (2017) 109:63-73. doi: 10.1016/j.addr.2016.02.002
121. Prieto-Vila M, Takahashi R-u, Usuba W, Kohama I, Ochiya T. Drug resistance driven by cancer stem cells and their niche. Int J Mol Sci. (2017) 18:2574. doi: 10.3390/ijms18122574
122. Zhihong C, Yijing C, Yichen L, Haobin H, Hui L. Signalling mechanism (s) of epithelial-mesenchymal transition and cancer stem cells in tumour therapeutic resistance. Clin Chim Acta (2018) 483:156-63. doi: 10.1016/j.cca.2018.04.033
123. Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T, et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell (2014) 159:499-513. doi: 10.1016/j.cell.2014.09.051
124. Doherty MR, Cheon H, Junk DJ, Vinayak S, Varadan V, Telli ML, et al. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proc Natl Acad Sci USA. (2017) 114:13792-7. doi: 10.1073/pnas.1713728114
125. Gaston J, Cheradame L, Yvonnet V, Deas O, Poupon M-F, Judde J-G, et al. Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents. Oncotarget (2016) 7:77205. doi: 10.18632/oncotarget.12858
126. Corrales L, Gajewski TF. Molecular pathways: targeting the stimulator of interferon genes (STING) in the immunotherapy of cancer. Clin Cancer Res. (2015) 21:4774-9. doi: 10.1158/1078-0432.CCR-15-1362
127. Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. (2015) 11:1018-30. doi: 10.1016/j.celrep.2015.04.031
128. Foote JB, Kok M, Leatherman JM, Armstrong TD, Marcinkowski BC, Ojalvo LS, et al. A STING agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in tolerized mice. Cancer Immunol Res. (2017) 5:468-79. doi: 10.1158/2326-6066.CIR-16-0284
129. Gadkaree SK, Fu J, Sen R, Korrer MJ, Allen C, Kim YJ. Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model. Head Neck (2017) 39:1086-94. doi: 10.1002/hed.24704
130. Spitzner M, Roesler B, Bielfeld C, Emons G, Gaedcke J, Wolff HA, et al. STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo. Int J Cancer (2014) 134:997-1007. doi: 10.1002/ijc.28429
131. Ashizawa T, Miyata H, Ishii H, Oshita C, Matsuno K, Masuda Y, et al. Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int J Oncol. (2011) 38:1245-52. doi: 10.3892/ijo.2011.957
132. Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim TY, et al. Phase I study of OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid tumors. Cancer Res Treat. (2015) 47:607. doi: 10.4143/crt.2014.249
133. Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs (2010) 13:394-403
134. Hu Y, Hong Y, Xu Y, Liu P, Guo D-H, Chen Y. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC. Apoptosis (2014) 19:1627-36. doi: 10.1007/s10495-014-1030-z
135. Dubois S, Miljkovic MD, Fleisher T, Hsu J, Waldmann TA, Conlon KC. Transient inhibition of the JAK1/3-STAT5 pathway by ruxolitinib is insufficient to produce clinical benefit in patients with indolent adult T-cell leukemia. Am Soc Hematol. (2017) 130:3840. Google Scholar
136. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood (2012) 119:4614-8. doi: 10.1182/blood-2011-12-400051
137. Pitroda S, Stack M, Liu GF, Song SS, Chen L, Liang H, et al. JAK2 inhibitor SAR302503 abrogates PD-L1 expression and targets therapy resistant non-small cell lung cancers. Mol Cancer Ther. (2018) 17:732-9. doi: 10.1158/1535-7163.MCT-17-0667
138. Wonganan O, He YJ, Shen XF, Wongkrajang K, Suksamrarn A, Zhang GL, et al. 6-Hydroxy-3-O-methyl-kaempferol 6-O-glucopyranoside potentiates the anti-proliferative effect of interferon α/β by promoting activation of the JAK/STAT signaling by inhibiting SOCS3 in hepatocellular carcinoma cells. Toxicol Appl Pharmacol. (2017) 336:31-9. doi: 10.1016/j.taap.2017.10.004
139. Mustachio LM, Lu Y, Kawakami M, Roszik J, Freemantle SJ, Liu X, et al. Evidence for the ISG15-specific deubiquitinase USP18 as an antineoplastic target. Cancer Res. (2018) 78:587-92. doi: 10.1158/0008-5472.CAN-17-1752
140. Zhao W, Qi J, Wang L, Zhang M, Wang P, Gao C. LY294002 inhibits TLR3/4-mediated IFN-β production via inhibition of IRF3 activation with a PI3K-independent mechanism. FEBS Lett. (2012) 586:705-10. doi: 10.1016/j.febslet.2012.01.016
141. Wei L, Bello AM, Majchrzak-Kita B, Salum N, Lewis MM, Kotra LP, et al. Small molecule agonists for the type I interferon receptor: an in Silico approach. J Interfer Cytokine Res. (2016) 36:180-91. doi: 10.1089/jir.2015.0123
142. Urin V, Levin D, Sharma N, Harari D, Schreiber G. Fine tuning of a type 1 interferon antagonist. PloS ONE (2015) 10:e0130797. doi: 10.1371/journal.pone.0130797
143. Simpson GR, Relph K, Harrington K, Melcher A, Pandha H. Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolyt. Virother. (2016) 5:1. doi: 10.2147/OV.S66083
144. Jackson JD, Markert JM, Li L, Carroll SL, Cassady KA. STAT1 and NF-κB inhibitors diminish basal interferon-stimulated gene expression and improve the productive infection of oncolytic HSV in MPNST cells. Mol Cancer Res. (2016) 14:482-92. doi: 10.1158/1541-7786.MCR-15-0427
145. Escobar-Zarate D, Liu Y, Suksanpaisan L, Russell SJ, Peng KW. Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. Cancer Gene Ther. (2013) 20:582. doi: 10.1038/cgt.2013.55
146. Felt SA, Droby GN, Grdzelishvili VZ. Ruxolitinib and polycation combination treatment overcomes multiple mechanisms of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. J Virol. (2017) 91:e00461-17. doi: 10.1128/JVI.00461-17
147. Ruf B, Berchtold S, Venturelli S, Burkard M, Smirnow I, Prenzel T, et al. Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma. Mol Ther Oncolyt. (2015) 2:15019. doi: 10.1038/mto.2015.19
148. Westcott MM, Liu J, Rajani K, D'Agostino R, Lyles DS, Porosnicu M. Interferon beta and interferon alpha 2a differentially protect head and neck cancer cells from vesicular stomatitis virus-induced oncolysis. J Virol. (2015) 89:7944-54. doi: 10.1128/JVI.00757-15
149. Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res. (2017) 77:839-50. doi: 10.1158/0008-5472.CAN-15-3142